Renin–angiotensin–aldosterone system inhibitors (RAASis) have been shown to reduce the risk of kidney failure and all-cause mortality in patients with chronic kidney disease (CKD) and of cardiovascular morbidity in patients with CKD or heart failure (HF) [1, 2]. This evidence concerns the gene REN and hydrops fetalis.